Literature DB >> 10733912

Different regulation of vascular endothelial growth factor expression by the ERK and p38 kinase pathways in v-ras, v-raf, and v-myc transformed cells.

E Okajima1, U P Thorgeirsson.   

Abstract

Here we show that vascular endothelial growth factor (VEGF) mRNA expression is up-regulated in oncogene transformed rat liver epithelial (RLE) cell lines and that the extracellular signal-regulated kinase (ERK) and p38 kinase differentially regulate the oncogene-mediated stimulation of VEGF. The highest level of VEGF mRNA expression was observed in the v-H-ras transformed RLE cell line, followed by the v-raf and v-myc transformed lines. The PD98059 MEK inhibitor was used to block the ERK pathway and SB203580 inhibitor to block the p38 pathway. The parent and the v-H-ras transformed RLE cell lines showed up-regulation of VEGF RNA expression through the ERK pathway and down-regulation of VEGF through the p38 pathway. VEGF was regulated in a comparable manner in a human breast carcinoma cell line. In the v-raf and v-myc transformed RLE lines, positive regulation of VEGF was transduced through the p38 pathway. These findings suggest that (1) oncogenic ras differs from raf and myc in the recruitment of the MAPK signaling pathways for VEGF regulation; (2) that VEGF is regulated in ras transformed and human cancer cell lines in a positive and negative manner by the ERK and p38 signaling pathways. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10733912     DOI: 10.1006/bbrc.2000.2386

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  5 in total

1.  ERKs activation and calcium signaling are both required for VEGF induction by vanadium in mouse epidermal Cl41 cells.

Authors:  Jingxia Li; Qiangsong Tong; Xianglin Shi; Max Costa; Chuanshu Huang
Journal:  Mol Cell Biochem       Date:  2005-11       Impact factor: 3.396

Review 2.  Models, mechanisms and clinical evidence for cancer dormancy.

Authors:  Julio A Aguirre-Ghiso
Journal:  Nat Rev Cancer       Date:  2007-11       Impact factor: 60.716

3.  Hypoxia inducible factor-1 alpha and vascular endothelial growth factor in biopsies of small cell lung carcinoma.

Authors:  M Ioannou; R Papamichali; E Kouvaras; I Mylonis; D Vageli; T Kerenidou; S Barbanis; A Daponte; G Simos; K Gourgoulianis; G K Koukoulis
Journal:  Lung       Date:  2009-08-26       Impact factor: 2.584

4.  c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression.

Authors:  Troy A Baudino; Catriona McKay; Helene Pendeville-Samain; Jonas A Nilsson; Kirsteen H Maclean; Elsie L White; Ann C Davis; James N Ihle; John L Cleveland
Journal:  Genes Dev       Date:  2002-10-01       Impact factor: 11.361

5.  Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.

Authors:  Nilofer S Azad; Edwin M Posadas; Virginia E Kwitkowski; Seth M Steinberg; Lokesh Jain; Christina M Annunziata; Lori Minasian; Gisele Sarosy; Herbert L Kotz; Ahalya Premkumar; Liang Cao; Deborah McNally; Catherine Chow; Helen X Chen; John J Wright; William D Figg; Elise C Kohn
Journal:  J Clin Oncol       Date:  2008-08-01       Impact factor: 50.717

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.